908. Outcomes Research: Myeloid Malignancies: Poster II

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p)

Comorbidities and outcomes in patients with Acute Myeloid Leukemia with and without type II diabetes mellitus admitted for chemotherapy A national inpatient sample analysis

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia AML

Outcomes of low intensity AML therapy based on treatment facility

Determining barriers to access first line treatment in high volume facilities in adolescents and young adults AYA with acute leukemias

Disaggregated outcomes of Asian Americans Native Hawaiian and Pacific Islander populations with Acute Myeloid Leukemia

Trends and race sex disparities in in hospital mortality of chemotherapy induced cardiomyopathy in hematologic malignancies

Characterizing palliative care utilization among patients with Acute Myeloid Leukemia AML Insights from analysis of AML hospitalizations in the United States

Social vulnerability and mortality trends in Acute Myeloid Leukemia in the United States adults 2010 to 2020 The paradoxical role of minority language communities

Real world hemoglobin Hb outcomes of patients with lower risk myelodysplastic syndromes LR MDS receiving first line 1L luspatercept or 1L erythropoiesis stimulating agents ESAs in the US

Integrating palliative care for adolescents and young adults with hematologic malignancies Insights from a dedicated french unit

Can we perform allogeneic hematopoietic cell transplantation HCT safely in patients with limited social supports and substantial psychosocial complexity

Assessment of real world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data

The burden of hematological malignancies in Latin America and the Caribbean A 30 year global burden of disease analysis

High dose ponatinib in Korean CML and Ph ALL  real world outcomes in early and heavily pretreated settings

Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm BPDCN Results of a real world analysis

Indirect treatment comparison ITC of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase CML CP

Global regional and national burden of myelodysplastic myeloproliferative and other hematopoietic neoplasms from 1990 to 2021 and projections to 2050 A systematic analysis for the global burden of disease study 2021

Impact of chemotherapy on survival in patients aged 75 years and older with Acute Myeloid Leukemia A contemporary population based analysis 2000–2022 from a national database

Real world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib PAC Results from the my PAC study

Real world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

Real world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm

Acute myeloid leukemia during the venetoclax era Trends in survival across demographic and socioeconomic groups

Patient reported outcome design conduct and reporting in australasian leukaemia lymphoma group ALLG cooperative group trials

Proportion of second hematologic malignancies linked to radiotherapy treatment in adults A cohort study in the US SEER cancer registries 2001 2022

Association of socioeconomic indicators with survival in chronic myeloid leukemia A retrospective analysis

Real world outcomes comparing the use of GLP 1 receptor agonists in patients with CML and comorbid obesity A propensity score matched analysis from global federated health research network

The effect of chronic kidney disease on outcomes in patients admitted with acute promyelocytic leukemia not in remission A nationwide analysis from 2016–2022